insights_auto
Kwa nini LGND imeongezeka kwa 2.31%?
Fahamu zaidichevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
US$ 301.81
arrow_upward
+2.31%(+6.81) Siku 1
US$ 301.81
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 9 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya LGND...
Fungua
US$ 294.79
Juu
US$ 304.78
Chini
US$ 294.32
Mtaji wa soko
6.02B
Wastani wa kiasi cha mauzo
elfu 247.38
Kiasi cha mauzo ya hisa
elfu 183.05
Uwiano wa bei ya hisa na mapato kwa kila hisa
32.10
Juu kwa wiki 52
US$ 326.63
Chini kwa wiki 52
US$ 175.89
EPS
US$ 9.40
Beta
1.06
Hisa za wawekezaji
19.94M
Idadi ya wafanyakazi
47
Fungua
US$ 294.79
Juu
US$ 304.78
Chini
US$ 294.32
Mtaji wa soko
6.02B
Wastani wa kiasi cha mauzo
elfu 247.38
Kiasi cha mauzo ya hisa
elfu 183.05
Uwiano wa bei ya hisa na mapato kwa kila hisa
32.10
Juu kwa wiki 52
US$ 326.63
Chini kwa wiki 52
US$ 175.89
EPS
US$ 9.40
Beta
1.06
Hisa za wawekezaji
19.94M
Idadi ya wafanyakazi
47
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Investing.com Nigeria
·
dakika 1 iliyopita
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock By Investing.com
Investing.com Canada
·
dakika 3 zilizopita
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com
Yahoo Finance
·
siku 3 zilizopita
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
Wasifu
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Kuhusu Ligand Pharmaceuticals Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi47
LilianzishwaSep 1987
Makao makuuJupiter, Florida, Marekani
Sekta-
Tovutiligand.com